New York - Even as biologic therapies become available, there will still be a place for acitretin, methotrexate and cyclosporin-based treatment protocols, according to Mark Lebwohl, M.D.
Establishing a Culture of Respect: Responding to Patient-Initiated Harassment
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity
New Advancements in Surgical Scar Revision